Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

NCT02892123 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT02892123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02892123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2016
Completion date
October 31, 2024
Enrollment
279 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

her2-expressing cancers